imatinib mesylate has been researched along with Giant Cell Arteritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balsalobre Aznar, J; Porta-Etessam, J | 1 |
| Cid, MC; García-Martínez, A; Hernández-Rodríguez, J; Lozano, E; Segarra, M | 1 |
1 review(s) available for imatinib mesylate and Giant Cell Arteritis
| Article | Year |
|---|---|
[Temporal arteritis: treatment controversies].
Topics: Aspirin; Benzamides; Giant Cell Arteritis; Glucocorticoids; Humans; Imatinib Mesylate; Immunosuppressive Agents; Methotrexate; Middle Aged; Optic Neuropathy, Ischemic; Piperazines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrimidines | 2010 |
1 other study(ies) available for imatinib mesylate and Giant Cell Arteritis
| Article | Year |
|---|---|
Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.
Topics: Benzamides; Cell Movement; Cell Proliferation; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Extracellular Matrix; Giant Cell Arteritis; Growth Substances; Humans; Imatinib Mesylate; Laminin; Piperazines; Platelet-Derived Growth Factor; Proteoglycans; Pyrimidines; Recombinant Proteins; Temporal Arteries; Tunica Intima | 2008 |